AntiCancers Oral Methioninase Overcomes Gemcitabine Resistance in Patient-Like Mouse Models of Pancreatic Cancer

Pancreatic cancer is lethal in about 95% of cases mostly due to failure
of first-line therapy gemcitabine. AntiCancer
Inc.’s oral methioninase (AC 00619), which is in late pre-clinical
development as an anti-cancer as well as an anti-aging drug, has now
been shown to overcome gemcitabine resistance in mouse models of human
pancreatic cancer, including AntiCancer’s patient-derived orthotopic
xenograft (PDOX®) mouse models. The new results are to be
published in the upcoming issue of Cancer Letters.

“Methioninase can change the paradigm of pancreatic cancer therapy,”
said Robert M. Hoffman, Founder of AntiCancer. “Methioninase is active
against all cancer types, since they all require excess methionine
compared to normal tissue, as seen in the use of radioactive methionine
in positron emission tomography (PET) imaging, which gives the strongest
PET signal due to the hunger of cancers for methionine,” said Hoffman.

With AntiCancer’s strong patent position on oral methioninase, a very
big commercial potential is expected. AntiCancer’s Methuselah
Pharmaceuticals subsidiary has been formed to develop oral methioninase
as a therapeutic for cancer, diabetes, obesity, hyperhomocysteinemia,
and to extend the normal healthy life span.

AntiCancer is also developing engineered bacteria to target all cancer
types and has the most patient-like mouse models of cancer, including
its PDOX® models, as well as MetaMouse®; AngioMouse®;
its histoculture drug response assay (HDRA®), which is an in
vitro test for first-line chemotherapy; and
hair-follicle-associated-pluripotent (HAP) stem cells for regenerative
medicine. AntiCancer was founded in 1984 with world headquarters in San
Diego and subsidiaries in Tokyo, Seoul, Beijing, and Nanjing.

View source version on

Leave a Comment